Closely tied to national welfare and the people’s livelihood, scientific and technological innovation in the medical industry is an essential part of the innovation endeavor in developing the Integrated National Demonstration Zone for Opening up the Services Sector and the China (Beijing) Pilot Free Trade Zone (the "Two Zones") . Since the launch of the building of the "Two Zones", Beijing has continuously deepened reform and furthered opening up within the medical service sector. Special efforts have been made in establishing a number of international hospitals and accelerating the incubation of medical R&D results to benefit more patients with modern health care services.

As the first hospital to promote collaborative innovation of medical institution and enterprises, Beijing Chao-Yang Hospital (Capital Medical University) has established a collaborative innovation center and joint laboratory together with enterprises. In 2020, in spite of the impact of COVID-19, the joint laboratory made steady progress in multiple aspects from joint innovation modalities to patent application, application of R&D results, introduction of innovative medical service programs, “digital medicine” brain cognitive training program, and clinical application bases for bio-immune cell therapy, and AI multidisciplinary clinic. In addition to meeting clinical needs, the joint lab also allowed for the multi-dimensional application of innovative results. With the introduction of innovative medical service programs, overall testing capabilities in the hospital have been further improved.

Along with the advancement of the "Two Zones", the Escol Innovative Medical Industry Cluster, to which Wispirit Technology is affiliated, is closing the complete loop of diagnosis and treatment in the future innovative medical field. Since becoming a pilot unit for further opening up of the service sector in Beijing, the Escol Innovative Medical Industry Cluster has been working closely with medical institutions and cooperating with hospitals to explore the integration of production, education, and research for commercialization of R&D results, and to establish a sound supporting mechanism for regulation and services. After nearly two years, the Escol Innovative Medical Industry Cluster has managed to cooperate with Beijing Chao-Yang Hospital (Capital Medical University), Beijing Anzhen Hospital (Capital Medical University), and other Grade-A tertiary hospitals. Under the principle of promoting the integration of production, education, and research, and boosting the transformation of R&D results, approximately 1,000 in-depth discussions have been conducted with clinical experts from different departments, and more than 250 projects were discussed to cover numerous fields such as the auxiliary diagnosis of genetic diseases and COVID-19 detection.

Since 2019, in the wake of the comprehensive pilot of further opening up the service sector in Beijing, a profit of over CNY 10 million was made at by the Escol Innovative Medical Industry Cluster at Beijing Chao-Yang Hospital (Capital Medical University). In the future, close cooperation will enhanced annually with more than 10 Grade-A tertiary medical institutions, including Beijing Tiantan Hospital and Beijing Shijitan Hospital. By establishing long-term strategic cooperation with medical institutions through joint laboratories, the annual innovation-based revenue at each medical institution is expected to reach CNY 30 million to 50 million.

(Note: Content source is from Beijing Daily.)